Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.
In Science this week: tumors with mismatch repair defects are responsive to immunotherapy, and more.
The proceeds from the offering will be used to fund the expansion of commercialization activities for the firm's colon cancer test, Cologuard.
A short pyknon motif on the lncRNA N-BLR appears to mediate its effect on cells' ability to metastasize and invade in colorectal cancer, researchers found.
Analysts have released notes to investors refuting the report's claims, calling the short thesis "flawed," and reiterating their ratings for Exact's stock.
The company, which beat Wall Street expectations on the top and bottom lines, said completed Cologuard test volume rose 150 percent over Q1 2016.
The investment bank said Exact has the opportunity to book $4 billion to $5 billion in revenues a year from its colon cancer screening test Cologuard.
The University of California, Los Angeles-led team said the approach outperformed two established classification methods.
The company said it completed 82,000 Cologuard tests during the quarter, a 114 percent growth in test volume during the three-month period.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.